Page 1930 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Index 1357

barriers, 67 Thienopyridines-associated thrombotic Thrombotic thrombocytopenic purpura
evidence, 67 thrombocytopenic purpura, (TTP), 858, 859, 901–902
implementation strategies, 67–69 859–860 acquired, 858
potential benefits, 66–67 Third-space fluid sequestration, 1046 diagnosis of, 861–863
role of intensivists, 68 Third spacing phenomenon, 256, 544 differentiation of
special challenges, 68–69 Thoracic aortic cross clamping, 1158 from hemolytic uremic syndrome, 862–
unintended consequences, 67 Thoracic aortic surgery, paralysis/paresis 863, 862t
Temperature regulation and hypothermia, after, 1072 from pregnancy-associated
spinal injuries and, 1150–1151 Thoracic cage deformity, 513–515, 513t, 514f complications, 863
Tempo of resuscitation, 254 effects on pulmonary circulation, 515 from systemic lupus erythematosus with
Temporary pacing, indications for, in acute gas exchange, 515 vasculitis, 863
https://kat.cr/user/tahir99/
myocardial infarction, respiratory mechanics, 514, 514f, 515f hereditary, 858
307–308, 308t Thoracic injuries requiring immediate hereditary and acquired idiopathic,
Tenecteplase, 299 intervention, 1153–1157 859, 859f
Tension pneumothorax, 1154, 1154f cardiac tamponade, 1155–1156 management of organ failure and
Terlipressin, 927 massive hemothorax, 1156 treatment-related complications,
Tertiary hyperparathyroidism, 960 open pneumothorax, 1154–1155, 1155f 864–865
Tetanus, 729–733 tension pneumothorax, 1154, 1154f pregnancy-associated, 860
antimicrobial therapy for, 732 Thoracic surgery emergencies, 1073 thienopyridines-associated, 859–860
antitoxin therapy for, 731–732 Thoracic ultrasonography, lung and pleura, treatment of, 863
cephalic, 730 205–206 Thymectomy, 826
clinical manifestations, 730 Thoracostomy, 505–509 Thymic hyperplasia, 826
cephalic, 730 chest tube insertion, 507–508 Thymoma, 826
generalized, 730 catheter size, 507 Thyroid disease, 986–996
localized, 730 contraindications, 508 amiodarone-induced thyrotoxicosis,
diagnosis and laboratory testing, 731, 731t placement, 508, 508f 994–995, 995t
epidemiology of, 729 risks, 508 decision to treat, 988, 988t
generalized, 730 drainage systems and chest tube goiter and acute airway
localized, 730 management, 508–509 obstruction, 990
minimizing muscle spasm for, 732 indications for, 505 hypothyroidism, 986–987
benzodiazepines, 732 pleural effusion, 507, 507f iodide-induced thyrotoxicosis, 996
neuromuscular blocking agents, 732 pneumothorax, 505–507, 506f levothyroxine overdose, 995
pathogenesis, 729–730 Thoracotomy myxedema coma, 988–990, 989t
prognosis, 733 anterolateral, 1157 neonatal thyrotoxicosis, 995–996
supportive care emergency, 1157–1160 nonthyroidal illness syndrome, 987
airway management of, 732 Three-phase time-sensitive model, of risks and management in thyrotoxic
managing autonomic instability, cardiac arrest therapy, patients, 993–994
732–733 172–173, 172f thyroid function studies, 987–988, 987t
treatment of, 731, 731t Thrombin time, 847–848 thyroid hormone physiology in critical
wound management of, 731 Thrombocytopenia, 328, 849, 893 illness, 987, 987f
Tetany, 959 anemia and, 870, 870t thyroid storm, 991–993, 991t, 992t
Therapeutic drug monitoring, 1239 correction of, and coagulopathy for routine thyrotoxicosis, 990–991, 990t
Therapeutic goals, defining, 3, 3f bedside procedures, 857 Thyroid function, head injury and, 1137
Therapeutic hypothermia, 174–179, dilutional, 850 Thyroid function studies, thyroid disease and,
809–810 drug and medication-induced, 850–851, 987–988, 987t
in cardiac arrest, 176–177, 176f, 177t 850t, 851t Thyroid hormone physiology in critical illness,
clinical applications, 177–178 etiology of, in intensive care unit patients, thyroid disease and, 987, 987f
future of induced, 179 849–853, 850t, 851t Thyroiditis, 826
history of induced, 174–175 heparin-induced, 851–852, 851t Thyroid storm
induced immune, 852 precipitating factors, 991
in myocardial infarction, 177 spurious, 849–850 thyroid disease and, 991–993, 991t, 992t
in stroke, 177 Thrombocytopenia syndrome, severe fever treatment of, 991–993, 992t
mechanisms of protection, 175–176, 175f with, 741–742 Thyrotoxicosis
risks of, 178 Thromboelastography, 848–849, 848f amiodarone-induced, 994–995, 995t
unresolved questions, 178–179 Thrombolysis, patient selection iodide-induced, 996
Therapeutic hypothesis, testing, 2, 3f of, 331 neonatal, 995–996
Therapeutic interventions, shock and, 261 Thrombolytic agents, 299 thyroid disease and, 990–991, 990t
Therapeutic Intervention Scoring System Thrombolytic therapy, 298–299, 299t, Ticagrelor, 303
(TISS) score, 90–91 329–332, 330t Ticarcillin-clavulanic acid, 699
Therapy, changing goal of, 4, 4t Thrombosis, cavernous sinus, 687 Tick-borne encephalitis virus (TBE), 672
Thermal coil, 246 Thrombosis factors, vascular physiology Tick paralysis, 828
Thermal filament, 246 and, 846 Tigecycline, 548, 699
Thermoregulation, 557 Thrombotic complications, 185, 901–902 Timing it right (TIR) framework, 110
Thiazide-induced hyponatremia, 948 Thrombotic microangiopathies, 852 Tissue corticosteroid resistance during
Thienopyridines, 300 acute renal failure and, 926 critical illness, 982

Index.indd 1357 23-01-2015 15:33:54